Yasir Y Elamin

Trials

Studies that name Yasir Y Elamin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:59 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT07415005 · Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

  M.D. Anderson Cancer Center · recruiting · Advanced Non-Small Cell Lung Cancer · principal investigator
• Ph2
  NCT06522360 · Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

  M.D. Anderson Cancer Center · withdrawn · Non-small Cell Lung Cancer · principal investigator
• Ph2
  NCT05364645 · Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

  SWOG Cancer Research Network · withdrawn · Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 · principal investigator
• Ph1
  NCT04837716 · Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

  M.D. Anderson Cancer Center · active not recruiting · Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 · principal investigator
• Ph1
  NCT04479306 · Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

  M.D. Anderson Cancer Center · completed · Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 · principal investigator
• Ph2
  NCT04268550 · Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

  SWOG Cancer Research Network · active not recruiting · Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 · principal investigator
• Ph1
  NCT03707938 · Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

  M.D. Anderson Cancer Center · active not recruiting · Advanced Lung Carcinoma, ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma · principal investigator
• Ph2
  NCT03066206 · Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

  M.D. Anderson Cancer Center · terminated · EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 09:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• SWOG Network Group Operations Center of the NCTN
  U10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026
  Named on NCT05364645, NCT04268550